In a report to clients March 6, Stanley initiated coverage of IMP with a “Buy” rating and 12-month price target of $4.00, ...

Following the release of the company’s fourth quarter results, Ventum analyst Andrew Semple has cut his price target on ...

Its fourth quarter results are in the books and Raymond James analyst Michael W. Freeman still thinks there is money to be ...

Following the company’s fourth quarter results, Desjardins analyst Gary Ho has raised his price target on CareRx Corp.